Satius Pharmaceuticals

Satius Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development of novel ophthalmic therapies, specifically targeting Dry Eye Disease (DED). The company's lead program, SAT-001, is a topical small molecule designed as a secretagogue to stimulate the production of the tear film's essential components. By focusing on restoring the natural balance of the ocular surface, Satius aims to address the underlying causes of DED rather than just managing symptoms. Headquartered in San Diego, the company was established by a team of experts with significant experience in eye care drug discovery and clinical development. The lead candidate has completed Phase 2 clinical testing, demonstrating potential in improving both signs and symptoms of ocular dryness.